13. Navigating Treatment Side Effects • Jason Starr, DO • Mayo Clinic • 2026 NCF Conference
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jason Starr, medical oncologist at Mayo Clinic in Jacksonville, Florida, presents “Navigating Treatment Side Effects.” Dr. Starr discusses how patients and care teams can balance treatment effectiveness with quality of life when using therapies for neuroendocrine cancers. He emphasizes the importance of early communication with the medical team, recognizing side effects promptly, holding medication when appropriate, using acute care resources when needed, and adjusting doses to find the right balance for each patient. This presentation reviews potential side effects and management strategies for somatostatin analogs, Lutetium-177 dotatate/Lutathera, PRRT, everolimus/Afinitor, CAPTEM, capecitabine, temozolomide, and tyrosine kinase inhibitors such as sunitinib and cabozantinib. Topics include fatigue, diarrhea, nausea, injection site pain, exocrine pancreatic insufficiency, blood sugar changes, gallbladder issues, bone marrow suppression, mouth sores, skin rash, blood pressure changes, wound healing concerns, thyroid issues, and medication interactions. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jason Starr, medical oncologist at Mayo Clinic in Jacksonville, Florida, presents “Navigating Treatment Side Effects.” Dr. Starr discusses how patients and care teams can balance treatment effectiveness with quality of life when using therapies for neuroendocrine cancers. He emphasizes the importance of early communication with the medical team, recognizing side effects promptly, holding medication when appropriate, using acute care resources when needed, and adjusting doses to find the right balance for each patient. This presentation reviews potential side effects and management strategies for somatostatin analogs, Lutetium-177 dotatate/Lutathera, PRRT, everolimus/Afinitor, CAPTEM, capecitabine, temozolomide, and tyrosine kinase inhibitors such as sunitinib and cabozantinib. Topics include fatigue, diarrhea, nausea, injection site pain, exocrine pancreatic insufficiency, blood sugar changes, gallbladder issues, bone marrow suppression, mouth sores, skin rash, blood pressure changes, wound healing concerns, thyroid issues, and medication interactions. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.